Putnam Investments LLC Bluebird Bio, Inc. Transaction History

Putnam Investments LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$2.94 - $5.23 $767,654 - $1.37 Million	-261,107 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$4.07 - $10.6 $185,473 - $483,052	45,571 Added 21.14%	261,107 $1.27 Million
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $1.93 Million - $3.52 Million	215,536 New	215,536 $2.15 Million
Q1 2020 May 15, 2020	SELL	$26.16 - $63.5 $218,828 - $531,177	-8,365 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$59.47 - $93.1 $497,407 - $778,688	-8,364 Reduced 50.0%	8,365 $768,000
Q2 2019 Aug 14, 2019	BUY	$75.84 - $105.21 $290,543 - $403,059	3,831 Added 29.7%	16,729 $2.13 Million
Q1 2019 May 15, 2019	SELL	$64.44 - $104.11 $3.92 Million - $6.33 Million	-60,776 Reduced 82.49%	12,898 $2.03 Million
Q3 2018 Nov 14, 2018	SELL	$88.86 - $117.49 $824,531 - $1.09 Million	-9,279 Reduced 11.19%	73,674 $10.8 Million
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $7.31 Million - $9.35 Million	-73,315 Reduced 46.92%	82,953 $13 Million
Q1 2018 May 15, 2018	BUY	$105.8 - $150.94 $16.5 Million - $23.6 Million	156,268 New	156,268 $26.7 Million

20.3M

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $315M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.